Anodyne Nanotech Raises $12.6 Million Series A to Advance Once-Weekly GLP-1 Patch ANN-101 into Phase I Clinical Trials

June 28, 2026

BioSpace USA

Overview

Anodyne Nanotech Inc., a clinical-stage biotechnology company, has secured $12.6 million in Series A funding to propel its once-weekly GLP-1 patch, ANN-101, for obesity treatment into Phase I clinical trials. The company’s HeroPatch™ platform utilizes solid microneedle technology, enabling effective, room-temperature stable delivery of large molecules like GLP-1 without injection or refrigeration. This capital injection will support ANN-101’s clinical development, accelerate the transdermal delivery platform, scale up manufacturing, and expand strategic partnership initiatives.

In Depth

Key Findings

Anodyne Nanotech Inc., a clinical-stage biotechnology company, has successfully completed a $12.6 million Series A funding round to accelerate its Phase I clinical trial for ANN-101, a once-weekly GLP-1 patch designed for obesity treatment. This significant funding marks a crucial step in advancing the company’s innovative HeroPatch™ transdermal delivery platform, addressing substantial unmet needs in chronic disease management.

Technical / Clinical Details

Anodyne Nanotech’s HeroPatch™ platform is built upon solid microneedle technology, differentiating it from traditional injectable formulations. This patch facilitates the effective transdermal delivery of relatively large peptide molecules, such as GLP-1, without the need for a conventional needle injection. A key advantage is the patch’s room-temperature stability, eliminating the requirement for cold chain storage and significantly improving patient convenience while reducing storage and distribution costs. The simplicity of once-weekly administration is expected to enhance treatment adherence among patients with obesity. The recently secured funding will establish the foundation to advance ANN-101’s Phase I clinical trials as planned, evaluating its safety and pharmacokinetic profile. The company positions this platform as a technology with the potential to revolutionize diabetes and obesity treatment.

Background & Context

GLP-1 receptor agonists have gained widespread recognition for their efficacy in treating type 2 diabetes and obesity, leading to rapid market expansion in recent years. However, many of these drugs require weekly or daily injections, which can be burdensome for patients. Furthermore, like many biologics, they necessitate refrigerated storage, posing challenges for maintaining the cold chain during distribution. Anodyne Nanotech’s transdermal patch offers a potential solution to these existing GLP-1 therapy challenges, aiming to reduce patient burden and provide a more accessible treatment option. This represents a critical advancement in promoting patient-centric treatment approaches for large-scale chronic disease management.

Strategic Significance & Outlook

The $12.6 million raised will primarily fund the execution of ANN-101’s Phase I clinical trials. Additionally, the capital will be utilized to accelerate the HeroPatch™ transdermal delivery platform’s technological development, scale up manufacturing capabilities, and expand future strategic partnership activities. Anodyne Nanotech plans to apply this platform to other large molecules and chronic disease therapeutics, beginning with ANN-101, potentially transforming drug delivery standards in the pharmaceutical industry. As clinical development progresses, the commercial value of this innovative technology is expected to further increase.

Source: https://www.biospace.com/press-releases/anodyne-nanotech-closed-a-12-6-million-series-a-to-advance-once-weekly-glp-1-patch-into-phase-i-clinical-trials

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.